Immunotherapy as a specific moleculer targeted therapy could modulate immune respons through cytotoxic CD8+ pathway so that generate anti-tumor activity on breast cancer. HER2/Neu is the one of tumor associated antigen which extensively studied to reduce cancer progression. CTLA-4 has important role in immune checkpoint blockade that it is used for studying breast cancer either in early or advanced level. In this review, we discussed principle of immunotherapy in tumor microenvironment and some kinds of active immunotherapies, which included cancer vaccination and immune checkpoint blockade. Majority of those immunotherapies are ongoing clinical trial. Hence, this becomes a promising new field in breast cancer therapies in a future and will ultimately change the current status of breast cancer therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.